USA flag logo/image

An Official Website of the United States Government

An Innovative Full-Thickness Human Skin Model for Increased Throughput…

Award Information

Agency:
National Science Foundation
Branch:
N/A
Award ID:
98928
Program Year/Program:
2010 / SBIR
Agency Tracking Number:
0945891
Solicitation Year:
N/A
Solicitation Topic Code:
BT.
Solicitation Number:
N/A
Small Business Information
Stratatech Corporation
505 S. Rosa Road, Suite 169 Madison, WI -
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2010
Title: An Innovative Full-Thickness Human Skin Model for Increased Throughput Screening in Drug Discovery
Agency: NSF
Contract: 0945891
Award Amount: $149,383.00
 

Abstract:

This Small Business Innovation Research (SBIR) Phase I project proposes to develop a full-thickness in vitro human skin model in a format enabling increased-throughput screening of compounds. The project will 1) develop culture conditions for production of fibroblast-derived dermal equivalents, 2) use these methods to manufacture skin models in a higher-throughput format, and 3) characterize the biochemical, structural, and functional properties of these tissues. Establishment of this model system will provide a consistent in vitro test platform for drug screening, assessment of transdermal delivery methods, dermal toxicology testing, and development of skin-specific disease models (i.e. melanoma). The developed process improvements will facilitate automation of tissue production and may be scalable to even smaller tissue formats. The broader impact of this research resides in the ability to provide a more reliable, accurate, and cost-effective method of determining the effects of drugs and other chemical compounds on human skin. Biotechnology, pharmaceutical, and consumer product companies devote substantial resources to screening new products and their components for dermal toxicity and permeability. Currently, testing is typically performed using monolayer cells or animal models, despite a well-documented inability for those systems to accurately predict drug efficacy in humans, a problem that contributes to the costly, high failure rate of drug candidates in clinical trials. In vitro skin models show the potential to improve screening capabilities, but current models are expensive and relatively low-throughput. The proposed model will provide accurate, efficient, and cost-effective chemical screening, while avoiding the ethical and regulatory concerns associated with animal testing.

Principal Investigator:

Kenneth R. Gratz
PhD
6084412756
kgratz@stratatechcorp.com

Business Contact:

Kenneth R. Gratz
PhD
6084412756
kgratz@stratatechcorp.com
Small Business Information at Submission:

Stratatech Corporation
505 South Rosa Road Suite 169 Madison, WI 53719

EIN/Tax ID: 392025292
DUNS: N/A
Number of Employees:
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No